Compounding Pharmacies HIV Treatment and Prevention Agents Immunization 
Pharmacy Times
JULY 16, 2025
Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. Zanubrutinib demonstrated sustained efficacy in CLL with del(17p), emphasizing the importance of BTK inhibitors in high-risk hematologic malignancies.
Pharmacy Times
JULY 25, 2025
Because of their ability to cover a wide array of bacteria, low adverse effect profile, and oral availability, cephalosporins are commonly used in the treatment of outpatient infections. Of note, only first-, second-, and third-generation cephalosporins are available as oral formulations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 24, 2025
Finerenone, a nonsteroidal MRA, shows promise in reducing HF events and atrial fibrillation, offering potential benefits over steroidal MRAs like spironolactone. Barriers to finerenone integration include cost, access, and existing MRA underutilization, with pharmacists crucial in educating prescribers and patients.
Pharmacy Times
JULY 18, 2025
Safe disposal options include DEA Take Back Days, pharmacy kiosks, law enforcement kiosks, mail-back envelopes, and home disposal methods.
Pharmacy Times
JULY 19, 2025
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. Jansen, PharmD Candidate , Mark A.
Pharmacy Times
JULY 1, 2025
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Pharmacy Times
JUNE 16, 2025
Although the use of colony-stimulating factors (CSFs) is well-established in mitigating severe FN, existing literature suggests there is only an approximate 3% difference in FN rates between various CSF agents.
Expert insights. Personalized for you.
65 
Let's personalize your content